ECHO
Status timeline
- 22 Jan 2026Application received from the International Bureau (Madrid)Sn Assigned For Sect 66a Appl From Ib
- 6 Mar 2026Assigned to an examining attorneyAssigned To Examiner
- 27 Mar 2026Office action issuedNon-Final Action Written
- 9 Jun 2026Response to office action filedTeas Response To Office Action Received
- 13 Jun 2026Approved for publicationApproved For Pub - Principal Register
- 14 Jul 2026Published for oppositionPublished For Opposition
- 1 Sep 2026Registered on the Principal RegisterRegistered-Principal Register
All 20 USPTO events
| 2026-09-01 | Registered-Principal Register |
| 2026-07-14 | Published For Opposition |
| 2026-07-14 | Official Gazette Publication Confirmation E-Mailed |
| 2026-07-09 | Notification Processed By Ib |
| 2026-07-08 | Notification Of Notice Of Publication E-Mailed |
| 2026-06-24 | Notice Of Start Of Opposition Period Created, To Be Sent To Ib |
| 2026-06-24 | Notification Of Possible Opposition Sent To Ib |
| 2026-06-13 | Approved For Pub - Principal Register |
| 2026-06-09 | Teas Response To Office Action Received |
| 2026-06-09 | Correspondence Received In Law Office |
| 2026-06-09 | Teas/Email Correspondence Entered |
| 2026-06-04 | Refusal Processed By Ib |
| 2026-05-15 | Non-Final Action Mailed - Refusal Sent To Ib |
| 2026-05-14 | Refusal Processed By Mpu |
| 2026-03-28 | Non-Final Action (Ib Refusal) Prepared For Review |
| 2026-03-27 | Non-Final Action Written |
| 2026-03-06 | Assigned To Examiner |
| 2026-01-27 | New Application Office Supplied Data Entered |
| 2026-01-27 | Application Filing Receipt Mailed |
| 2026-01-22 | Sn Assigned For Sect 66a Appl From Ib |
Goods & services
Class 40 Materials treatment
Custom biomanufacture of therapeutic iPSC-based cells, iPSC-based cells for use in cell therapies and iPSC-based allogeneic edited cells for use in therapies, for others; custom biomanufacture of iPSC-based allogeneic cells for use in cell therapies
Class 42 Technology & SaaS
Scientific research, design and technological development services in the fields of scientific iPSC-based cell cultures, iPSC-based cell therapies, and iPSC-based gene-edited cell therapy; scientific research, design and development of manufacturing processes in the fields of cell culture, cell therapy, and gene edited cell therapy, for others; scientific research consultation services in the field of biotechnology, specifically in relation to iPSC-based cell culture, iPSC-based cell therapy, or iPSC-based gene edited cell therapy manufacturing
Source & freshness
Source: USPTO Trademark Applications bulk data. This record was last updated by the USPTO file dated 31 Aug 2026; the index was built on 20 Nov 2026 and covers USPTO data through 31 Aug 2026. Open the official USPTO record (TSDR) → If the two differ, the USPTO record is correct.